Stryker Corp.
SYK
Get informed when a big investor buys or sells
+ FollowEarnings Call Q2 2026
July 30, 2026 - AI Summary
Exclusive for Stockcircle Pro members
Sign up
Current Fair Value
3.6% upsideUndervalued by 3.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $124.86 Billion |
|---|---|
| Enterprise Value | $136.82 Billion |
| Dividend Yield | $3.48 (1.07%) |
| Earnings per Share | $8.49 |
| Beta | 0.78 |
| Outstanding Shares | 383,500,000 |
Return
| Return on Equity | 15.55% |
|---|---|
| Return on Assets | 7.78% |
| Return on Invested Capital | 11.98% |
Valuation & Multiples
| P/E Ratio | 33.47 |
|---|---|
| PEG | 75.49 |
| Price to Sales | 4.86 |
| Price to Book Ratio | 5.25 |
| Enterprise Value to Revenue | 5.3 |
| Enterprise Value to EBIT | 27.68 |
| Enterprise Value to Net Income | 36 |
| Total Debt to Enterprise | 0.11 |
| Debt to Equity | 0.64 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.2500▼ 62.30% |
|---|---|
| Total Calls | 3,200▼ 99.55% |
| Total Puts | 800▼ 99.87% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 11.14%▼ 67.02% |
|---|---|
| Total Invested | $13.42B▼ 86.35% |
| Investors Holding | 1,050▼ 1298.00% |
ESG Score
No data
About Stryker Corp.
40,000 employees
CEO: Kevin Lobo Stryker is one of the world's leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Orthopaedics, Medical and Surgical, and Neur...
Relevant Senate Committees
This committee provides critical analysis and revenue estimates for all tax legislation, directly influencing corporate tax structures and capital investment credits that impact Stryker's financial planning and profitability.
This committee's control over taxation, trade, and entitlement spending (e.g., Medicare pricing) directly affects Stryker's profitability, market access, and the reimbursement rates for its products.
This committee allocates specific federal spending, and its subcommittees directly determine funding for healthcare programs, research, and government purchasing of medical equipment, directly impacting Stryker's revenue streams from the federal sector.
This committee directly regulates the FDA, which is the primary approval and oversight body for all medical devices. Its decisions on drug approval processes and healthcare legislation directly impact Stryker's product pipeline and market access.
Stryker, as a medical device manufacturer, is a direct supplier to government healthcare contractors, including the Department of Veterans Affairs, making funding decisions highly relevant.